Almotriptan
As of the edition of 20 October 2026, Almotriptan is a small molecule: marketed, first approved in 1999 (ES); acts on HTR1B, HTR1D and HTR1F.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2004
- Kind
- Small molecule
- Brand name
- Axert
- First approved
- 29 December 1999 (ES)
- Approvals on record
- 5 in 4 regions
- Holder of the most recent approval
- Almirall; 2 holders in all
- Registered trials
- 8, 1 stopped early
- Disease areas
- Nervous system; Chemically induced; Ear, nose and throat; Infections; Lungs and airways; Mental health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
6 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product6 company-target rows are on route B because of Almotriptan.
See the 6 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 2 | 2 | 0 | 0 |
| Phase 4 | 6 | 4 | 0 | 1 |
| All trials | 8 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Johnson & Johnson | Acquired holder and Lead sponsor of trials | 2003 to now |
| Almirall | Applicant | 2004 to now |
| Pfizer | Originator | 2001 to 2011 |